Latest Conference Articles

This Maui Derm NP+PA Fall session discusses the latest advancements in hidradenitis suppurativa treatment, the evolving therapeutic landscape, and the critical need for timely diagnosis and aggressive care.

Researchers analyzed APPs treatment and perceptions on AD in studies focusing on patient satisfaction and patients with skin of color.

At Maui Derm NP+PA Fall 2024, Ted Rosen, MD, and George Hightower, MD, PhD, review the landscape of infectious diseases that can have dermatologic involvement, including viral, bacterial, fungal, and parasitic illnesses.

Catch up on coverage from the first day of the Maui Derm NP+PA Fall 2024 conference in Nashville, Tennessee.

Hawkes highlights groundbreaking therapies for psoriasis, including new oral medications and IL-23 inhibitors.

At Maui Derm NP+PA Fall 2024, Melodie Young, MSN, ANP-c, reviews new treatment options for pediatric patients with psoriasis and details the difference in disease manifestation between adults and children.

The IL-13 inhibitor, recently FDA-approved for moderate to severe AD, reached all primary endpoints in the study focusing on patients with skin of color.

George Martin, MD, and Ted Rosen, MD, reprise their popular session on new therapies and products with a fast and furious rundown of the current armamentarium across disease states.

At Maui Derm NP+PA Fall, Sheila Fallon Friedlander, MD, reviews key findings for the pediatric population from recent dermatology literature, covering topics like cutaneous Crohn’s disease, interrupting the atopic march, advancements in gene therapy, and more.

Ahead of the next 3 months of the year, Dermatology Times wants to know what conferences and meetings you plan to attend between October and December. Share your thoughts with us by September 25.

Dermatology Times asked our readers to share what conferences they are looking forward to in the third quarter of 2024.

Earlier this summer, Meghan Heberton, MD, emphasized the importance and growth of the subspecialty.

Renata Block, MMS, PA-C, interviews fellow colleagues to discuss conference highlights, Psoriasis Awareness Month, community advocacy, and more.

Michele Ramien, MD, discusses biologic therapies for pediatric dermatology, focusing on their impact on vaccines, managing side effects, and tailoring treatment.

Naiem Issa, MD, PhD, shared highlights from his sessions on the 1726 nm laser for acne, atopic dermatitis disease modification, advances in hidradenitis suppurativa, and microneedling techniques for vitiligo.

Dermatology Times asked our readers to share what conferences they are looking forward to in the third quarter of 2024.

Linda Stein Gold, MD, reviews data presented at SPD and elaborates on study design, methodology, and results.

Four APPs emphasized the vital role of advanced practice providers in improving patient care and expanding service access.

David Rosmarin, MD, shared his insights on the study in a Q&A with Dermatology Times.

Catch up on coverage from the 2024 Society for Pediatric Dermatology Annual Meeting in Toronto, Ontario, Canada.

The AICHI study found a significant prevalence of severe primary axillary hyperhidrosis in children in Japan, according to a poster presented at the SPD's annual meeting.

Metz and Tollefson share insights on efficient practice management, work-life balance, and exciting developments in pediatric dermatology.

Smidt and Hunt offer insights on navigating pediatric dermatology decision-making, emphasizing learning from clinical scenarios and fostering a culture of feedback and improvement.

Oleogel-10 exhibited potential to alleviate the physical, emotional, and economic strain of dressing changes, according to a poster presented at the SPD's annual meeting.

Catch up on coverage from the third and final day of the 2024 Society for Pediatric Dermatology Annual Meeting in Toronto, Ontario, Canada.

Tapinarof cream 1% has proven to be an effective and safe treatment for atopic dermatitis in diverse populations, according to a poster presented at the SPD's annual meeting.

TMB-001 0.05% demonstrates promising efficacy and safety in treating moderate to severe congenital ichthyosis, according to a poster presented at the SPD's annual meeting.

In this episode, Vikash Oza, MD, and James Treat, MD, discuss their SPD 2024 session (debate) revolving around the topic: Does food trigger eczema?